Fw: LDN Website Update - October 18, 2010

[Guest guest]

From: joelgluck <joelgluck@...>Subject: [low dose naltrexone] LDN Website Update - October 18, 2010low dose naltrexone Date: Sunday, October 17, 2010, 9:52 PM

LDN Website Update - October 18, 2010www.low dose naltrexone.org / www.ldninfo.orgLATEST NEWS AS OF OCTOBER 2010[Note: for the complete version of this information, with active links, please visit http://www.low dose naltrexone.org/ldn_latest_news.htm ]Met-enkephalin Successful in Treating Advanced Pancreatic CancerJill , MD, Professor of Gastroenterology at Hershey Medical Center, and colleagues have reported the following:"In a prospective phase II open-label clinical trial, 24 subjects who failed standard chemotherapy for advanced pancreatic cancer were treated weekly with OGF [opioid growth factor; aka met-enkephalin] 250 mcg/kg intravenously. Outcomes measured included clinical benefit, tumor response by radiographic imaging, quality of life, and survival... Clinical benefit response was experienced by 53%

of OGF-treated patients compared to historical controls of 23.8% and 4.8% for gemcitabine and 5-fluorouracil (5-FU), respectively. Of the subjects surviving more than eight weeks, 62% showed either a decrease or stabilization in tumor size by computed tomography. The median survival time for OGF-treated patients was three times that of untreated patients (65.5 versus 21 days, p < 0.001)."The original report was published as Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. JP, Bingaman SI, Mauger DT, Harvey HH, Demers LM, Zagon IS. Open Access J Clin Trials. 2010 Mar 1; 2010(2):37-48.[Ed. Note: Low Dose Naltrexone has been shown to double or triple one's daily output of met-enkephalin.]International LDN Aware Week Observed October 18-24A video which celebrates LDN has been made available for this occasion by Elsegood of LDN Research Trust. See http://www.youtube.com/?v=_z5g0WRNin8.LDN Website Editors email@...